ClinicalTrials.gg
RecruitingNCT07026656VAP-DxUpdated Aug 3, 2025

Pre-clinical Diagnosis Using Integrated Microbial and Host Response Signatures to Improve Outcomes From Ventilator-associated Pneumonia in Critically Ill Children

An observational study in Ventilator Associated Pneumonia ( VAP), sponsored by University of Cambridge. Recruiting at 1 site in United Kingdom. Open to participants aged 1 Month to 16 Years. Per ClinicalTrials.gov, last updated 2025-08-03.

Sponsored by University of Cambridge · Observational

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
1 Month to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Pneumonia, Ventilator-Associated with a site in United Kingdom — 2 open to participants now, 3 under way, none of them phase 3. Pneumonia, Ventilator-Associated · United Kingdom.

Started
2025
the only one that year
Observational
5 of 11
1 open now
Registered
11th of 11
by date
Lead sponsor
1 of 11
University of Cambridge

Among the 11 studies in Pneumonia, Ventilator-Associated with a site in United Kingdom, this one is the only one that started in 2025, is one of 5 observational ones, and was the 11th registered.

Pneumonia, Ventilator-Associated

420 studies on the registry are indexed under Pneumonia, Ventilator-Associated; 83 are open to participants now.

Browse Pneumonia, Ventilator-Associated studies →

Open to participants now

2 of the 11 studies in Pneumonia, Ventilator-Associated with a site in United Kingdom are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 47 Pneumonia, Ventilator-Associated studies recruiting now, 36 (77%) set no upper age limit and 6 (13%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 1 Month to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Pneumonia, Ventilator-Associated with a site in United Kingdom, or all of them as a file.
02

Study summary

Ventilator-associated pneumonia (VAP), defined as pneumonia occurring 48 hours after initiation of invasive mechanical ventilation, is insidious in onset and severe in consequence. It is a critical issue affecting 10-20% of the 26,000 children admitted to the paediatric intensive care unit (PICU) each year. Infection typically leads to extended PICU stay, prolonged invasive mechanical ventilation, and increased mortality.

Despite its clinical significance, VAP remains poorly defined, as current diagnosis relies on non-specific criteria and the ability to obtain clinically meaningful cultures. VAP, deviates from conventional pneumonia, potentially originating, from tissue damage, changes to immune processes, and migration of gastrointestinal bacteria into the lung; all associated with prolonged mechanical ventilation. These factors, in combination with the clinical instability of PICU patients, mean that clinicians aggressively start antibiotic therapy despite a paucity of evidence to suggest the best regime. As a result, suspected VAP has been shown to account for nearly 40% of antibiotic exposure in the PICU, which has significant implications on anti-microbial resistance (AMR).

To address these challenges, novel diagnostic therapies are needed to optimise the treatment of VAP. These therapies should utilise our current understanding of the pathophysiology of VAP development, specifically, the infiltration of the lung microbiome by gut and oral bacteria during prolonged mechanical ventilation. To achieve this, molecular testing should be promoted allowing for rapid identification of lung pathogens. There is also growing evidence, for the investigation of predictive biomarkers for VAP available in both the blood and lungs, which when integrated into protocols may enhance diagnostic accuracy. These novel techniques may improve clinical outcomes for affected children while addressing the economic impact of prolonged hospital stays and mitigating AMR risks in PICUs.

03

Conditions studied

  • Ventilator Associated Pneumonia ( VAP)

Keywords

  • Respiratory Tract Infection
  • Immunology
  • Genomics
  • Paediatric Intensive Care Unit (PICU)
04

Who can participate

Ages eligible
1 Month to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Critically Ill Children Requiring Mechanical Ventilation For Greater Than 48 Hours

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PICU Admission
  • Requires 48 Hours Of Mechanical Ventilation

Exclusion criteria

Exclusion Criteria:

  • Imminent death or palliative care pathway planned
  • Existing tracheostomy at time of admission
  • Known patient
  • Patient received a full course of systemic antimicrobials in the previous 6 weeks.
  • Known or suspected tuberculosis (TB).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Ventilator Associated Pneumonia Group

    Critically ill children who develop VAP during their PICU journey will be assigned to the VAP group

  • Non-Ventilator Associated Pneumonia Group

    All patients who fit eligibility criteria for study and do not go on to develop VAP

06

What researchers measure

Primary outcomes

  1. Characterise temporal shifts in microbial composition and the corresponding host immune response during prolonged mechanical ventilation

    Serial metagenomic profiling of the lung microbiome to establish microbial shifts. Concurrently, cytokines collected from blood and endotracheal aspirates will be taken to assess immune changes.

    Time frame: 3 years

  2. Characterise the AMR burden in VAP and its role in shaping the microbiome during infection.

    Utilise metagenomic sequencing to identify AMR genes present on microbes and relate this to VAP development

    Time frame: 3 years

  3. Develop statistical and/or machine learning models leveraging these signatures independently, or in combination, to identify putative microbial and host biomarkers for early VAP diagnosis

    Time frame: 3 years

Secondary outcomes

  1. Prevalence of VAP

    Number of critically ill children requiring mechanical ventilation who develop VAP compared to those who do not

    Time frame: 3 years

  2. 30 day mortality

    Mortality status of patients at 30 days

    Time frame: 3 years

  3. Time To Extubation

    Total Time Intubated

    Time frame: 3 years

  4. Utilisation Of VAP Prevention Bundle

    Time frame: 3 years

  5. Culture Results

    Microbiological Results For Each Patient

    Time frame: 3 years

  6. Days free of antimicrobial therapy in PICU at 7 days

    Days free of antimicrobial therapy during the first 7 days of a patients admission to PICU

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Patient data will be collected and stored on REDcap Safe Haven. All data that is shared will be anonymised to ensure it is not identifiable.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Sep 2027, 29 months after the start.

Of 63 non-industry observational studies under Pneumonia, Ventilator-Associated, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 38. This study's planned 29 months is above that.

Counting every sponsor, half of 63 studies reached it within 20 months; a quarter within 12 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2025
First posted
Jun 18, 2025
StartActual
Apr 14, 2025
Primary completionEst.
Sep 30, 2027
CompletionEst.
Sep 30, 2027
Last update
Aug 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07026656
Responsible party
Nazima Pathan (FRCPCH PhD, University of Cambridge) — Principal investigator
First posted
Jun 18, 2025
Start date
Apr 14, 2025
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Aug 3, 2025

Study contacts

Nazima Pathan, FRCPCH PhD
Contact
np409@medschl.cam.ac.uk
+441223 805000
Don Laing, MBChB, BMedSci (Hons)
Contact
dml57@cam.ac.uk
+441223 805000
Nazima Pathan, FRCPCH PhD
principal investigator · Department of Paediatrics, University of Cambridge

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion